Rockville is home to biotechnology companies, research organizations, government contractors, and scientific teams working across drug discovery, diagnostics, immunology, and translational research. These programs often require antibodies that are designed for a specific target, assay format, or biological application. A commercially available reagent may be useful for routine work, but it may not provide the specificity, affinity, functional activity, or application compatibility required for a specialized project.
Precision Antibody provides custom antibody development services for Rockville biotech and federal research programs. Its capabilities include custom monoclonal and polyclonal antibody development, anti-idiotype antibody generation, antibody production and purification, biochemical and biophysical characterization, and application-specific screening.
Each project begins with the scientific objective. Target biology, antigen format, intended assay, sample matrix, binding requirements, and downstream use can all influence how an antibody program should be designed. Precision Antibody uses this information to develop a project strategy that aligns antibody generation and screening with the required application.
The company operates from its laboratory in Columbia, Maryland. It can support organizations in Rockville without suggesting that it maintains a physical office or laboratory in the city.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
A custom antibody project is not simply a process for producing an antibody that binds to a target. The antibody must also perform reliably in the environment where researchers intend to use it.
An antibody selected through a general binding assay may behave differently in a sandwich ELISA, flow based assay, immunohistochemistry workflow, neutralization study, internalization assay, or biological sample. For that reason, application requirements should help guide antigen planning, screening, clone selection, and characterization from the beginning.
Precision Antibody develops project strategies around the client’s target and intended use. Its website identifies experience with antibodies for diagnostic applications, therapeutic applications, anti-idiotype programs, neo epitope-specific targets, and Immuno-MRM work.
For Rockville research teams, this tailored approach can be relevant when a project involves:
A novel protein, peptide, small molecule, or other antigen
A target that lacks a suitable commercial antibody
An existing reagent that does not perform in the required assay
A need for monoclonal antibodies with defined binding properties
Capture and detection antibody pair development
Pharmacokinetic or anti-drug antibody assay support
Functional screening for neutralization or internalization
Production and purification of a selected antibody
Biochemical, biophysical, or molecular characterization
Ownership and transfer of developed clones
Defining these needs before development begins helps establish appropriate screening criteria. It also gives the scientific team and antibody developer a clearer basis for evaluating candidate clones.
Anti-idiotype antibodies recognize unique determinants in the variable region of another antibody. In a biopharmaceutical program, the target antibody is often a drug antibody or therapeutic antibody that must be measured in biological samples.
This creates a specialized development challenge. The selected anti-idiotype antibody must distinguish the drug antibody within a sample that may contain a large concentration of endogenous antibodies and other components capable of causing interference.
Precision Antibody provides custom anti-idiotype antibody development for programs that require reagents directed against the variable region of a drug antibody. Its process can include the development and evaluation of monoclonal antibodies for pharmacokinetic studies and related assay needs.
Anti-idiotype antibodies can be grouped according to where and how they bind to the drug antibody. Two important categories are anti-paratope and anti-idiotope antibodies.
An anti-paratope antibody binds at or near the drug antibody’s antigen-binding site. Because it competes with the original antigen, its binding can be affected when the drug antibody is already bound to that antigen.
An anti-idiotope antibody recognizes another determinant within the variable region without interfering with antigen binding in the same way. This difference can influence whether a reagent is appropriate for detecting free drug, total circulating drug, or another defined assay measurement.
The best category depends on the intended analytical question. A project designed to measure unbound drug may require different binding behavior from one intended to measure total drug in a biological matrix.
Some anti-idiotype programs require a matched capture and detection pair for a sandwich ELISA. In this format, the two antibodies must bind the drug antibody in a compatible manner. Strong individual binding does not automatically mean that two clones will function effectively as a pair.
Pair selection can involve evaluating:
Whether both antibodies can bind the target simultaneously
Binding affinity and dissociation behavior
Epitope compatibility
Assay signal and background
Performance in the intended sample matrix
The level of serum or matrix interference
The measurement objective of the assay
Precision Antibody reports using epitope binning through Octet technology to support antibody pair selection. It also evaluates high affinity, low off-rate candidates and considers matrix effects when selecting capture and detection combinations for pharmacokinetic applications.
The meaning of an assay result depends partly on what the reagent detects. If an anti-paratope antibody cannot bind an antigen-bound drug antibody, the assay may primarily measure free drug. A noncompeting anti-idiotype antibody may be more suitable when the objective is to detect a broader portion of circulating drug.
These requirements should be discussed during project planning. Clarifying the measurement objective early helps connect antibody selection with the intended pharmacokinetic or analytical use.
A reagent may bind well in a purified system but perform differently in serum or another complex biological matrix. Endogenous antibodies, soluble proteins, target molecules, and other components can affect assay background or apparent binding.
Matrix evaluation is therefore an important part of determining whether an anti-idiotype antibody is suitable for the intended assay. Researchers should identify the planned sample type and relevant matrix conditions when discussing a new project.
Monoclonal antibodies originate from individual antibody-producing clones, which allows researchers to work with reagents having defined and reproducible binding characteristics. They are commonly considered when a project requires target specificity, clone continuity, characterization, or future production from the same source.
Precision Antibody develops custom mouse and rat monoclonal antibodies and offers fully human monoclonal antibody development. Its broader development capabilities support research tools, diagnostic applications, therapeutic discovery, and functional studies.
Antigen selection can influence the immune response and the types of antibodies generated. A full-length protein, peptide, small molecule conjugate, cell associated target, or other antigen format may expose different epitopes and produce different candidate profiles.
Useful planning questions include:
Which region of the target should the antibody recognize?
Should the antibody bind native, denatured, or modified target?
Is a specific post-translational modification important?
Must the antibody distinguish between related proteins or isoforms?
Will the final assay use purified material, cells, tissue, serum, or another matrix?
Is binding alone sufficient, or is a biological function required?
Precision Antibody states that its antigen design, immunization, and screening strategies are tailored to the project’s intended application. This helps connect the development campaign with the result the Rockville research team actually needs.
Screening determines which antibody-producing clones should move forward. The best screening method depends on the intended use.
A project for sandwich ELISA development may prioritize compatible antibody pairs, assay signal, and matrix performance. A flow based application may require recognition of a native target on the cell surface. A neutralization project must evaluate biological activity rather than binding alone.
Application-specific screening can reduce the risk of selecting a clone that binds in an initial test but fails in the final workflow. Candidate selection can consider specificity, affinity, signal strength, functional activity, cross-reactivity, and other project-defined criteria.
Precision Antibody also offers fully human monoclonal antibody development using Trans Chromosomics mouse technology. The platform is designed to generate antigen-specific clones that produce fully human IgG.
This option may be relevant to research teams evaluating therapeutic antibody candidates or programs where a fully human sequence is preferred. The appropriate development route still depends on the target, intended use, required antibody format, and downstream plan.
Antibody development does not end when a binding clone is identified. Characterization helps researchers compare candidates and understand whether their properties align with the intended application.
Precision Antibody offers antibody characterization services that include binding analysis through Octet and Biacore platforms. Its listed capabilities also include class and subclass determination, isoelectric point determination, analytical size exclusion chromatography, variable heavy and light chain sequencing, stability assays, and epitope mapping.
Binding affinity describes the overall strength of the interaction between an antibody and its target. Kinetic measurements provide additional information about how quickly that interaction forms and how quickly it dissociates.
A low dissociation rate can be important in applications where the antibody must remain bound during an assay or biological process. However, the most useful binding profile depends on the project. Affinity should be considered together with specificity, epitope, functional performance, matrix behavior, and assay format.
Octet can support efficient screening and comparison of multiple candidates. Biacore can provide detailed analysis of binding kinetics. The appropriate platform and study design depend on the questions the research team needs to answer.
A binding result does not prove that an antibody performs a required biological function. Functional evaluation becomes important when a project involves neutralization, receptor activation, receptor internalization, or another defined cellular response.
Precision Antibody lists specialized services that include:
Ligand neutralization assays
Receptor internalization assays
Flow based assays
Immunohistochemistry
Custom enzyme immunoassays
Biological assays
Oncology panel profiling
The relevant assay should reflect the intended mechanism or application. Researchers planning functional antibody development should define the desired activity, biological model, controls, and decision criteria as early as possible.
Two antibodies can bind the same target while producing different functional outcomes. They may recognize different epitopes, approach the target at different angles, or interfere with different molecular interactions.
For this reason, binding screens and functional screens answer separate questions. A successful development plan may use binding data to identify candidates and functional testing to determine which candidates are most relevant to the research objective.
Maintaining candidates that recognize different epitopes can give a research team more options. Epitope diversity can support pair development, mechanistic studies, target characterization, and the selection of antibodies with distinct biological effects.
Epitope binning or mapping can help researchers understand these relationships before choosing final clones.
Once a suitable clone has been identified, researchers may need purified antibody for additional experiments, assay development, validation, or broader studies.
Precision Antibody offers antibody production and purification from hybridomas, stable cell lines, transiently transfected cells, and ascites. Its website describes production from milligram through gram scale, depending on the selected method and project requirements.
Available downstream work includes affinity purification, buffer exchange, concentration adjustment, vialing, and delivery according to defined specifications. Production planning should consider the amount of antibody needed, required purity, preferred buffer, concentration, storage conditions, and planned application.
Precision Antibody states that clients own the clones developed through their projects and that the company does not retain ownership. It also indicates that it can exchange confidentiality and service agreements, including CDA, NDA, and MSA documents.
Ownership can be important for biotech, pharmaceutical, academic, and federal research programs that may need continued access to a clone, future production, sequencing, engineering, or transfer into another workflow.
Custom antibody development contains several connected stages. Precision Antibody uses milestone-based projects and provides information as work progresses.
A typical anti-idiotype development workflow described by the company may include:
Reagent procurement
Immunogen preparation and immunization
Fusion and cloning
Application-specific screening
Expansion and cryopreservation of selected clones
Antibody characterization
Delivery of final clones
The exact scope and timing should be established in the statement of work for the individual project. Target complexity, reagent availability, screening needs, assay development, and additional characterization can affect the final plan.
Regular milestone information gives the client an opportunity to understand progress and review findings as the project moves from one stage to the next.
Research organizations in Rockville may work at different stages of discovery and development. One team may need a monoclonal antibody as a research tool, while another may require anti-idiotype reagents for a drug program. Others may need functional screening, antibody characterization, production, or a combination of these services.
Precision Antibody’s location in Columbia keeps its laboratory operations within Maryland while allowing it to support project teams in Rockville. This geographic relationship does not replace scientific fit, but it may make a Maryland antibody development company relevant to organizations seeking a regional service provider.
Potential project types include:
Novel target and biomarker research
Therapeutic antibody discovery
Pharmacokinetic assay reagent development
Anti-drug antibody assay support
Diagnostic antibody development
Antibody pair generation
Cell based functional studies
Research reagent development
Antibody production and purification
Sequence, binding, and biophysical characterization
The service combination should be determined by the project’s scientific objective rather than by a standard package.
Clear project information helps the antibody developer recommend a practical strategy. A complete project brief does not need to answer every technical question, but it should explain what success means for the research team.
Provide available information about the target, including its sequence, molecular form, species, known domains, related proteins, and relevant modifications. Explain whether the antibody should recognize a linear sequence, conformational structure, native cell surface target, drug antibody, or another form.
If the target belongs to a closely related protein family, identify the proteins that should not be recognized. These details can influence antigen design and counter-screening.
Specify how the antibody will be used. ELISA, flow cytometry, immunohistochemistry, neutralization, internalization, pharmacokinetic analysis, and other applications can require different antibody properties.
The screening plan should reproduce the intended application as closely as practical. When this is not possible during early screening, the project can use staged evaluation to narrow candidates before testing them in the final format.
Selection criteria help the team compare candidates objectively. Criteria may include:
Target specificity
Minimum binding response
Affinity or off-rate requirements
Recognition of native or denatured target
Lack of binding to related proteins
Performance in serum or another matrix
Compatibility with a second antibody
Neutralizing or internalizing activity
Required isotype or species
Production characteristics
Not every project requires all of these criteria. Prioritizing the most important factors helps keep the campaign aligned with the intended result.
Consider what will happen after a clone is selected. The project may require purified antibody, additional production, sequencing, cryopreservation, conjugation, epitope analysis, stability evaluation, or transfer of the clone.
Planning these requirements early can prevent delays between development and downstream experiments.
A custom antibody is worth considering when no suitable commercial reagent exists, an available antibody does not work in the required application, the target is novel, or the project requires control over clone selection and future production.
Commercial antibodies can remain appropriate for common targets and routine assays. The decision should depend on the specificity, validation, continuity, and application requirements of the project.
The development team generally needs information about the drug antibody, intended assay, desired measurement, sample matrix, and required reagent format. It is especially important to clarify whether the assay should detect free drug, total drug, or another defined form.
Available antigen, sequence, isotype, formulation, and binding information can also help with project planning.
They recognize different features of the drug antibody and may respond differently when the drug is bound to its antigen. An anti-paratope antibody competes at the antigen-binding region, while a noncompeting anti-idiotope antibody binds elsewhere within the variable region.
That distinction affects assay design and what portion of the drug antibody population may be measured.
Not necessarily. Antibody performance can change with assay format, target presentation, sample type, fixation method, and biological context. An antibody that performs well in a purified binding assay may not recognize a native cell surface target or function effectively in a biological assay.
Application-specific screening helps identify candidates that are more closely aligned with the final use.
Kinetic analysis provides information about association and dissociation behavior in addition to overall binding strength. This can help distinguish antibodies that appear similar in an endpoint binding assay.
Kinetic data should be considered with specificity, function, matrix performance, epitope, and other application requirements.
Yes. Its verified service capabilities include antibody production, purification, characterization, sequencing, epitope mapping, conjugation, stability testing, cell banking, and several functional assays. The exact downstream work should be defined in the project scope.
The company lists its laboratory address in Columbia, Maryland, not Rockville. This page describes services available to Rockville research organizations and does not claim that Precision Antibody has a physical location in the city.
Precision Antibody states that the clones developed for a client belong to that client and that the company does not retain ownership. Specific ownership, confidentiality, delivery, and documentation terms should be confirmed in the applicable project agreement.
A productive antibody program begins with a clear connection between the target, the intended application, and the criteria used to select candidates. This is particularly important for anti-idiotype development, pharmacokinetic assay reagents, functional monoclonal antibodies, and projects involving complex or novel targets.
Precision Antibody offers Rockville biotech and federal research teams access to custom antibody development, application-specific screening, antibody characterization, and downstream production from its Maryland laboratory.
Researchers can begin by sharing their target information, intended application, sample matrix, preferred antibody format, screening requirements, and anticipated downstream needs. Precision Antibody can then use those details to prepare a project scope and development strategy suited to the scientific objective.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
